Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Aeglea BioTherapeutics, Inc. (AGLE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Aeglea BioTherapeutics, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 235,358 $ 34,863 Marketable securities — 20,848 Development receivables 1,646 375 Prepaid expenses and other current assets 2,882 6,172 Total current assets 239,886 62,258 Restricted cash 1,317 1,553 Property and equipment, net — 3,220 Operating lease right-of-use assets 2,316 3,430 Other non-current assets 10 683 TOTAL ASSETS $ 243,529 $ 71,144 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 2,854 $ 677 Forward contract liability 164,382 — CVR liability 10,500 — Operating lease liabilities 4,331 625 Deferred revenue 930 517 Accrued and other current liabilities 28,427 12,837 Related party accounts payable 20,810 — ..." |
|
| 08/11/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 08/07/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/07/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/28/2023 |
SC 13G
| Polar Capital Holdings Plc reports a 5% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 07/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp... |
| 07/18/2023 |
SC 13G
| Logos Global Management LP reports a 8.1% stake in Aeglea Biotherapeutics, Inc. |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G
| Venrock Healthcare Capital Partners III, L.P. reports a 10% stake in Aeglea BioTherapeutics, Inc. |
| 07/06/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/30/2023 |
3
| Fairmount Funds Management LLC (10% Owner) has filed a Form 3 on Aeglea BioTherapeutics, Inc. |
| 06/30/2023 |
SC 13D
| Fairmount Funds Management LLC reports a 20% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 06/30/2023 |
3
| Turtle Cameron (Chief Operating Officer) has filed a Form 3 on Aeglea BioTherapeutics, Inc. |
| 06/30/2023 |
3
| HENDERSON MICHAEL THOMAS (Director) has filed a Form 3 on Aeglea BioTherapeutics, Inc. |
| 06/30/2023 |
4
| Alspaugh Jonathan (President and CFO) has filed a Form 4 on Aeglea BioTherapeutics, Inc.|
Txns:
| Granted 19,787,969 options to buy
@ $0.3, valued at
$5.9M
|
|
| 06/30/2023 |
4
| Cox Russell J. (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.|
Txns:
| Granted 1,950,000 options to buy
@ $0.3, valued at
$585k
|
|
| 06/30/2023 |
4
| Magovcevic-Liebisch Ivana (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.|
Txns:
| Granted 1,950,000 options to buy
@ $0.3, valued at
$585k
|
|
| 06/30/2023 |
4
| Smith Hunter C (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.|
Txns:
| Granted 1,950,000 options to buy
@ $0.3, valued at
$585k
|
|
| 06/30/2023 |
4
| Lawton Alison Frances (Director) has filed a Form 4 on Aeglea BioTherapeutics, Inc.|
Txns:
| Granted 1,950,000 options to buy
@ $0.3, valued at
$585k
|
|
| 06/30/2023 |
SC 13G
| EcoR1 Capital Fund Qualified, L.P. reports a 6.4% stake in Aeglea Biotherapeutics, Inc. |
| 06/30/2023 |
SC 13G
| Deep Track Capital, LP reports a 10% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
|
|
|